Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Ieva Drulyte

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Journal of Nanobiotechnology|March 10, 2025
A bivalent spike-targeting nanobody with anti-sarbecovirus activityIris C Swart, Oliver J Debski-Antoniak, Aneta Zegar, et al.
Nature|October 4, 2023
Sialoglycan binding triggers spike opening in a human coronavirusMatti F Pronker, Robert Creutznacher, Ieva Drulyte, et al.
Scientific Reports|June 15, 2026
Discovery of membrane channel modulators via DNA encoded library screening using native like membrane protein nanoparticlesFrancesco V Reddavide, Trine L Toft-Bertelsen, Ieva Drulyte, et al.
Mabs|June 3, 2025
Computational design of therapeutic antibodies with improved developability: efficient traversal of binder landscapes and rescue of escape mutationsFrédéric A Dreyer, Constantin Schneider, Aleksandr Kovaltsuk, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 20, 2023
A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike proteinVito Thijssen, Daniel L Hurdiss, Oliver J Debski-Antoniak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2024
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer ModelsSheryl M Gough, John J Flanagan, Jessica Teh, et al.
Science Immunology|April 26, 2022
An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concernWenjuan Du, Daniel L Hurdiss, Dubravka Drabek, et al.
Nature Biotechnology|July 21, 2022
The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variantsSylvia Rothenberger, Daniel L Hurdiss, Marcel Walser, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Journal of Nanobiotechnology|March 10, 2025
A bivalent spike-targeting nanobody with anti-sarbecovirus activityIris C Swart, Oliver J Debski-Antoniak, Aneta Zegar, et al.
Nature|October 4, 2023
Sialoglycan binding triggers spike opening in a human coronavirusMatti F Pronker, Robert Creutznacher, Ieva Drulyte, et al.
Scientific Reports|June 15, 2026
Discovery of membrane channel modulators via DNA encoded library screening using native like membrane protein nanoparticlesFrancesco V Reddavide, Trine L Toft-Bertelsen, Ieva Drulyte, et al.
Mabs|June 3, 2025
Computational design of therapeutic antibodies with improved developability: efficient traversal of binder landscapes and rescue of escape mutationsFrédéric A Dreyer, Constantin Schneider, Aleksandr Kovaltsuk, et al.
Proceedings of the National Academy of Sciences of the United States of America|June 20, 2023
A broad-spectrum macrocyclic peptide inhibitor of the SARS-CoV-2 spike proteinVito Thijssen, Daniel L Hurdiss, Oliver J Debski-Antoniak, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 31, 2024
Oral Estrogen Receptor PROTAC Vepdegestrant (ARV-471) Is Highly Efficacious as Monotherapy and in Combination with CDK4/6 or PI3K/mTOR Pathway Inhibitors in Preclinical ER+ Breast Cancer ModelsSheryl M Gough, John J Flanagan, Jessica Teh, et al.
Science Immunology|April 26, 2022
An ACE2-blocking antibody confers broad neutralization and protection against Omicron and other SARS-CoV-2 variants of concernWenjuan Du, Daniel L Hurdiss, Dubravka Drabek, et al.
Nature Biotechnology|July 21, 2022
The trispecific DARPin ensovibep inhibits diverse SARS-CoV-2 variantsSylvia Rothenberger, Daniel L Hurdiss, Marcel Walser, et al.
Pageof 2